KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding

Feb.26
KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding
KT&G said it plans to cancel all treasury shares it holds, totaling 10,866,189 shares, representing about 9.5% of shares outstanding, in line with Korea’s third amendment to the Commercial Act requiring companies to cancel repurchased shares within one year. The company also disclosed progress on its shareholder-return plan and multiple agenda items for next month’s shareholders meeting.

Key Takeaways

 

  • Event: On Feb. 25, KT&G’s board announced a plan to cancel all treasury shares held—10,866,189 shares—about 9.5% of KT&G’s shares outstanding;
  • Background: Korea’s third amendment to the Commercial Act emphasizes cancelling repurchased shares within one year;
  • Next steps: For future stock compensation for employees and executives, KT&G plans to purchase shares directly in the market and dispose of them;
  • Shareholders meeting: On March 26, KT&G plans to consider a treasury-share holding and disposal plan, charter revisions, and audit-committee-related agenda items.

 


2Firsts, February 26, 2026 

 

According to Chosun Biz, KT&G said, while resolving to convene its 39th regular general meeting of shareholders, that it will cancel all treasury shares it currently holds, totaling 10,866,189 shares, or about 9.5% of KT&G’s shares outstanding.

 

The move reflects the legislative intent of the “third amendment to the Commercial Act,” which has passed a plenary session of Korea’s National Assembly. The amendment centers on mandating the cancellation of treasury shares, requiring companies that repurchase their own shares to cancel them within one year.

 

KT&G also said that if it uses shares in the future for stock compensation to employees and executives, it will instead purchase shares directly in the market and dispose of them.

 

In a 2024 disclosure, KT&G presented a corporate-value enhancement plan centered on shareholder returns of KRW 3.7 trillion (about $2.85 billion, calculated at roughly KRW 1,300 per $1) over four years—KRW 2.4 trillion (about $1.85 billion) in dividends plus KRW 1.3 trillion (about $1.00 billion) in treasury-share purchases and cancellations. Since then, from 2024 through last year, KT&G said it returned KRW 1.2 trillion (about $923 million) to shareholders in dividends and carried out treasury-share purchases and cancellations totaling KRW 1.1 trillion (about $846 million), involving 9.05 million shares.

 

The report also said KT&G has completed the cancellation of 10.1 million treasury shares already held. Including new treasury-share purchases and cancellations, cumulative treasury-share cancellations amount to 14.3% (a total of 19.15 million shares) compared with the number of shares outstanding at the end of 2023.

 

At the shareholders meeting scheduled for March 26, KT&G plans to submit agenda items including approval of a plan for holding and disposing of treasury shares, approval of the financial statements, partial amendments to the articles of incorporation—such as increasing the number of separately elected audit committee members to two—and the appointment of outside directors who will serve on the audit committee.

 

In particular, considering the intent of the amended Commercial Act focused on protecting minority shareholder rights, KT&G plans to revise its articles of incorporation to allow an integrated cumulative voting system by deleting a provision that had classified the “representative director-president” and other directors into separate groups for the application of cumulative voting.

 

In addition, the report said the appointment of two new outside directors who will serve on the audit committee (one to be separately elected) and approval of the limit on directors’ remuneration are expected to be submitted as agenda items.

 

KT&G said that, to actively reflect the intent of the amended Commercial Act, it submitted the cancellation of all treasury shares held as an agenda item for this shareholders meeting, adding that it will continue to work to enhance corporate value and increase shareholder value based on what it described as best-in-class corporate governance competitiveness in Korea.

 

Cover image source: Chosun Biz

Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia’s withdrawal of its appeal in a landmark liquid-nicotine case has left a High Court ruling that struck down the 2023 nicotine exemption in force, bringing liquid and gel nicotine used in vaping products back under the Poisons Act 1952. At the same time, the Control of Smoking Products for Public Health Act 2024 continues to provide a regulatory framework for vaping products, creating uncertainty over retail sales, taxation and existing inventory. MPs are calling for nicotine vape sales and excise collection to stop, including refunds of more than RM354 million collected since 2023, while industry and consumer groups are asking the government to clarify the current legal position.
Sep.04
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
According to CBS Los Angeles on August 27, 2026, California lawmakers have passed Assembly Bill 762, which would phase out disposable, battery-embedded nicotine vapes in the state. If signed by Governor Gavin Newsom, manufacturing and importation of the covered products would be prohibited beginning January 1, 2027, followed by a sales ban on January 1, 2028. Driven primarily by concerns over electronic waste, lithium-battery fires and environmental pollution, the legislation would further shift California’s legal vape market toward rechargeable, refillable or replaceable-pod devices.
Aug.28
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
DOJO launched the BLAST10K Fresh in the UK on September 4, 2026, introducing its INSTA-JUICED™ technology and a new 0+10ml structure that keeps e-liquid separated from the coil before activation. The device features a 1000mAh rechargeable battery, COREX BLAST dual-mesh technology and SSS leak-resistant technology, with a manufacturer-rated capacity of up to 10,000 puffs. It also retains compatibility with existing 2+8ml pods across the BLAST ecosystem. The launch introduces eight new flavors, including Matcha Strawberry, which DOJO describes as an industry first.
Market
Sep.04
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11